GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BioMaxima BMX.WA · PLN

Health Care · GPW · 🇵🇱 Poland

Compare

8.60

-0.92%

Close of 9 Nov 2026, in PLN

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in PLN, from our data supplier.

FY2025

Revenue

PLN 60.9m

FY2016FY2025

Net income

PLN 105,000

FY2016FY2025

Free cash flow

PLN 1.3m

FY2016FY2025

Shareholders' equity

PLN 48.1m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenuePLN 60.9mPLN 52.9mPLN 46.8mPLN 143.9mPLN 79.1mPLN 61.6mPLN 30.5mPLN 30.8mPLN 31.6mPLN 27.0m
Research and development——————PLN 278,303PLN 476,884PLN 717,591PLN 668,966
Operating income−PLN 135,000PLN 1.3mPLN 728,000PLN 34.9mPLN 13.7mPLN 10.5mPLN 683,341−PLN 247,473PLN 1.1mPLN 1.5m
Net incomePLN 105,000PLN 535,000PLN 586,000PLN 28.9mPLN 10.2mPLN 7.9m−PLN 13,506−PLN 481,985PLN 805,683PLN 1.2m
Diluted earnings per share0.030.130.146.482.301.77-0.00-0.130.220.33

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsPLN 77.5mPLN 76.3mPLN 73.8mPLN 74.4mPLN 61.9mPLN 53.4mPLN 43.3mPLN 44.0mPLN 27.3mPLN 23.4m
Cash and short-term investmentsPLN 1.7mPLN 909,000PLN 1.5mPLN 12.9mPLN 3.0mPLN 4.4mPLN 505,844PLN 1.0mPLN 1.4mPLN 766,996
Total liabilitiesPLN 23.8mPLN 29.0mPLN 26.8mPLN 22.0mPLN 32.7mPLN 27.5mPLN 26.8mPLN 27.1mPLN 9.9mPLN 6.6m
DebtPLN 14.5mPLN 14.6mPLN 12.9mPLN 5.8mPLN 17.3mPLN 12.4mPLN 12.1mPLN 15.8mPLN 5.0mPLN 3.7m
Shareholders' equityPLN 48.1mPLN 47.3mPLN 47.0mPLN 52.5mPLN 29.2mPLN 19.9mPLN 16.4mPLN 16.8mPLN 17.3mPLN 16.8m
Shares outstanding4m4m4m4m4m4m4m4m4m4m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsPLN 2.3m−PLN 152,000PLN 1.6mPLN 37.1m−PLN 132,000PLN 4.0mPLN 4.9mPLN 2.1mPLN 1.8mPLN 1.4m
Capital spending−PLN 999,000−PLN 2.3m−PLN 18.1m−PLN 9.9m−PLN 4.5m−PLN 1.9m−PLN 1.6m−PLN 17.4m−PLN 2.2m−PLN 376,118
Free cash flowPLN 1.3m−PLN 2.4m−PLN 16.5mPLN 27.2m−PLN 4.6mPLN 2.1mPLN 3.3m−PLN 15.3m−PLN 327,854PLN 1.1m
Dividends paid——−PLN 2.1m−PLN 1.9m−PLN 1.1m−PLN 1.1m−PLN 1.1m−PLN 1.1m−PLN 390,803−PLN 608,000

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenuePLN 13.8mPLN 14.1mPLN 17.7mPLN 15.0mPLN 12.9mPLN 15.3mPLN 15.9mPLN 13.0m
Operating income−PLN 590,000PLN 407,000PLN 333,000−PLN 515,000−PLN 668,000PLN 925,000PLN 1.0m−PLN 1,000
Net incomePLN 362,000PLN 328,000PLN 423,000−PLN 304,000−PLN 603,000PLN 589,000PLN 967,000−PLN 251,000
Diluted earnings per share0.090.080.10-0.07-0.140.140.23-0.06
Cash from operations—−PLN 2.0mPLN 2.0m———PLN 1.0m−PLN 2.0m
Total assetsPLN 79.7mPLN 79.5mPLN 77.5mPLN 77.3mPLN 77.9mPLN 79.5mPLN 76.3mPLN 74.9m
Cash and short-term investmentsPLN 1.2mPLN 423,000PLN 1.7mPLN 1.1mPLN 528,000PLN 576,000PLN 909,000PLN 472,000
DebtPLN 10.2mPLN 14.4mPLN 12.6mPLN 14.9mPLN 11.2mPLN 15.1mPLN 14.3mPLN 14.2m
Shareholders' equityPLN 48.3mPLN 48.0mPLN 48.1mPLN 46.8mPLN 47.2mPLN 47.8mPLN 47.3mPLN 46.4m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-24.9%-0.2%10.7%
Net income-84.6%-57.9%-23.1%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin1.0%12.1%13.7%11.2%
Net margin0.6%9.9%10.9%8.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings481.283.9117.54.011.415.6-1115.9-32.723.114.7
Price to sales0.80.81.50.81.52.00.50.50.60.7

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 16 Jun 2023.

FY2023FY2022FY2021FY2017FY2016FY2015
Paid in the year0.500.450.250.050.200.10

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.